Both classes of drugs stimulate AMPARs by increasing extracellular glutamate levels and elevate BDNF levels in brain areas implicated in depression [22,145,220,222,224,235,236,237,238], facilitating the adaptive rewiring of pathological neurocircuitry and explaining their sustained therapeutic effects [52]. This evidence concerns the gene BDNF and depressive symptom measurement.